DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dr - 2 Joseph Rizzo - 2 semaglutide - 1 ” - 1 ” Susan Mollan - 1 Disha - 1 Sanjay Gupta - 1 Chanapa - 1
Top related locs:
Boston Massachusetts Novo semaglutide Chicago
Top related orgs:
Novo Nordisk - 2 Harvard Medical School - 2 Service - 1 Business - 1 Ophthalmology - 1 CNN — - 1 Mass - 1 CNN - 1

Search resuls for: "Joseph Rizzo"


2 mentions found


☆ Patients on Ozempic are developing a rare form of sudden blindness, doctors say
  + stars: | 2024-07-03 | by ( Hilary Brueck | ) www.businessinsider.com   time to read: +3 min
Eye doctors in Boston have started to notice a small but worrisome uptick in cases of a rare type of sudden blindness among patients taking semaglutide. (Semaglutide is the active ingredient in two Novo Nordisk drugs: Ozempic for type 2 diabetes and Wegovy for obesity.) Rare, and notableThe number of patients on semaglutide who developed NAION was tiny: Out of more than 16,000 eye patients in Massachusetts included in this six-year retrospective investigation, only 37 people on semaglutide developed NAION. Patients with diabetes and high blood pressure have always been at an increased risk of developing eyesight issues. (Novo Nordisk is working on another, separate study, testing whether semaglutide might be useful in treating diabetic retinopathy.)
Persons: semaglutide, Dr, Joseph Rizzo Organizations: Service, Business, Ophthalmology, Novo Nordisk, Harvard Medical School Locations: Boston, Massachusetts, Novo, semaglutide
☆ Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness
  + stars: | 2024-07-03 | by ( Deidre Mcphillips | ) edition.cnn.com   time to read: +6 min
CNN —People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. Semaglutide prescriptions have soared in the US, which could raise the number of people at risk for a potential side effect. But the large number of people who are taking semaglutide should raise confidence that the absolute risk of developing NAION as a result is rare.
Persons: ”, Joseph Rizzo, ” Susan Mollan, Disha, Dr, Sanjay Gupta, Chanapa, Andrew Lee, ” Narang Organizations: CNN —, Mass, Novo Nordisk, CNN, Harvard Medical School, ”, University Hospitals Birmingham, Endeavor Health, CNN Health, US Food and Drug Administration, FDA, American Academy of Ophthalmology, Houston Methodist Hospital Locations: Chicago
0 next >>
Total: 2